Research Study

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma
Principal Investigator 
Kevin Song

Overview

Body Locations and Systems 
Blood
Disorders and Conditions 
Multiple Myeloma
ClinicalTrials.gov# 
nct02685826
Status 
Recruiting
Study Start/End 
Jun 19, 2017 to Feb 29, 2024
Locations 
Vancouver General Hospital
Name/Title 
Sarah MacEwan/Research Coordinator
Phone 
604-875-4111 ext: 22966
Purpose of Study 

This is a multicenter, open-label, Phase 1/2 study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subjects with Newly diagnosed multiple myeloma (NDMM).

The study will consist of a dose-finding phase as well as a parallel dose-expansion phase to determine the optimal regimen

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.